Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A peroxisome biogenesis disorder which is due to defect in PEX7 or PEX5. This includes rhizomelic chondrodysplasia punctata due to defect in PEX7 or PEX5, and adult Refsum Disease due to defects in PEX7.
Biomarker and diagnostic research for non-Zellweger spectrum disorder has been reported in the published literature.
No clinical trials have been registered for non-Zellweger spectrum disorder.
4 publications have been identified in PubMed for non-Zellweger spectrum disorder. Research spans Diagnostic / Biomarker (25%), Clinical Trial Publication (25%), and Basic Science / Preclinical (25%).
Gao XD (2026). [PMID: 41981313](https://pubmed.ncbi.nlm.nih.gov/41981313/). *Nat Biomed Eng*. [Basic Science / Preclinical]
Bonaventura E (2025). [PMID: 41133696](https://pubmed.ncbi.nlm.nih.gov/41133696/). *International journal of neonatal screening*. [Clinical Trial Publication]
Cheung ACT (2025). [PMID: 40112482](https://pubmed.ncbi.nlm.nih.gov/40112482/). *Molecular genetics and metabolism*. [Diagnostic / Biomarker]
Mares Beltran CF (2024). [PMID: 39062617](https://pubmed.ncbi.nlm.nih.gov/39062617/). *Genes*. [Epidemiology / Natural History]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 4:32 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
AI-curated news mentioning non-Zellweger spectrum disorder
Updated Apr 14, 2026
Research demonstrates that in vivo base editing effectively rescues liver pathophysiology and peroxisome dysfunction in a mouse model of Zellweger spectrum disorder. This breakthrough could pave the way for novel therapeutic strategies targeting this rare genetic condition.